1. Home
  2. EDIT vs SANG Comparison

EDIT vs SANG Comparison

Compare EDIT & SANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDIT
  • SANG
  • Stock Information
  • Founded
  • EDIT 2013
  • SANG 1984
  • Country
  • EDIT United States
  • SANG Canada
  • Employees
  • EDIT N/A
  • SANG N/A
  • Industry
  • EDIT Biotechnology: Biological Products (No Diagnostic Substances)
  • SANG Computer Software: Programming Data Processing
  • Sector
  • EDIT Health Care
  • SANG Technology
  • Exchange
  • EDIT Nasdaq
  • SANG Nasdaq
  • Market Cap
  • EDIT 179.1M
  • SANG 213.1M
  • IPO Year
  • EDIT 2016
  • SANG 2021
  • Fundamental
  • Price
  • EDIT $2.88
  • SANG $6.20
  • Analyst Decision
  • EDIT Buy
  • SANG
  • Analyst Count
  • EDIT 12
  • SANG 0
  • Target Price
  • EDIT $6.20
  • SANG N/A
  • AVG Volume (30 Days)
  • EDIT 3.5M
  • SANG 2.3K
  • Earning Date
  • EDIT 08-06-2025
  • SANG 05-08-2025
  • Dividend Yield
  • EDIT N/A
  • SANG N/A
  • EPS Growth
  • EDIT N/A
  • SANG N/A
  • EPS
  • EDIT N/A
  • SANG N/A
  • Revenue
  • EDIT $35,837,000.00
  • SANG $238,264,000.00
  • Revenue This Year
  • EDIT N/A
  • SANG N/A
  • Revenue Next Year
  • EDIT N/A
  • SANG $2.91
  • P/E Ratio
  • EDIT N/A
  • SANG N/A
  • Revenue Growth
  • EDIT N/A
  • SANG N/A
  • 52 Week Low
  • EDIT $0.91
  • SANG $4.08
  • 52 Week High
  • EDIT $6.05
  • SANG $7.99
  • Technical
  • Relative Strength Index (RSI)
  • EDIT 74.64
  • SANG 66.61
  • Support Level
  • EDIT $2.48
  • SANG $6.23
  • Resistance Level
  • EDIT $3.24
  • SANG $6.49
  • Average True Range (ATR)
  • EDIT 0.25
  • SANG 0.11
  • MACD
  • EDIT 0.07
  • SANG 0.04
  • Stochastic Oscillator
  • EDIT 84.84
  • SANG 82.17

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

About SANG Sangoma Technologies Corporation

Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.

Share on Social Networks: